K. Banks

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

J. Zanchetta, G. Hattersley, B. Leder, 2015, The Journal of clinical endocrinology and metabolism.

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects

T. Haverty, Ming‐yi Hu, K. Tencer, 2021, Clinical pharmacology in drug development.

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial

A. Harris, J. Bilezikian, D. Hans, 2017, Osteoporosis International.

Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX‐02 in Patients With Nephropathic Cystinosis

T. Haverty, P. Goodyer, Ming‐yi Hu, 2020, Journal of clinical pharmacology.

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

J. Zanchetta, G. Hattersley, B. Leder, 2015, The Journal of clinical endocrinology and metabolism.